JS Link, Inc. (KOSDAQ:127120)

Market Cap	251.98B
Revenue (ttm)	14.27B
Net Income (ttm)	-15.16B
Shares Out	26.98M
EPS (ttm)	-723.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	57,950
Average Volume	134,168
Open	9,980.00
Previous Close	10,020.00
Day's Range	9,620.00 - 9,980.00
52-Week Range	2,440.00 - 10,780.00
Beta	-0.21
RSI	60.95
Earnings Date	Aug 14, 2025

About JS Link

JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In additio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 83
• Stock Exchange: KOSDAQ
• Ticker Symbol: 127120

Financial Performance

In 2024, JS Link's revenue was 15.91 billion, a decrease of -27.52% compared to the previous year's 21.95 billion. Losses were -10.80 billion, 93.0% more than in 2023.